BioSpace News Archive

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced updates for its Phase 1 clinical trial evaluating IDE397 in patients having solid tumors with MTAP deletion and Phase 1/2 clinical trial evaluating darovasertib combination therapies in metastatic uveal melanoma.

MannKind Corporation appreciates the recent efforts of the Centers for Medicare and Medicaid Services in conjunction with the Medicare Administration Contractors to implement a policy change to the Local Coverage Determination L33822, allowing the approval to Medicare patients living with diabetes to select both Afrezza® and Continuous Glucose Monitors.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced it will conduct a mouse study to investigate the efficacy of MN-166 in a murine model of chlorine-induced lung injury and lethality.

Regenerative Patch Technologies LLC announced the presentation of results from its Phase 1/2a clinical trial of the CPCB-RPE1 implant for advanced, dry age-related macular degeneration.

Ault Global Holdings, Inc. a diversified holding company, announced it has entered into a securities purchase agreement to acquire up to 40% of the current equity in Adtech Pharma, Inc., an innovative biotechnology company, for $3 million.

CMR Surgical, a global surgical robotics business, announces that it has raised $600 million in a Series D financing.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, announced that the Company will be added to the small-cap Russell 2000® Index and the broad-market Russell 3000® Index effective after the US market opens on June 28, 2021 as a result of the annual Russell index reconstitution.

The Company’s annual report for the 12 months ended 31 December 2020, will be posted to shareholders in the coming days, along with a notice of general meeting.

Clene Inc. and its wholly owned subsidiary Clene Nanomedicine, Inc., announced that it has been added as a member of the U.S. small-cap Russell 2000® Index and the all-cap Russell 3000® Index, effective after the U.S. market opens today, June 28, 2021, as part of the 2021 Russell indexes reconstitution.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, announced that it has submitted a Marketing Authorisation Application for mitapivat to the European Medicines Agency for the treatment of adults with pyruvate kinase deficiency in the European Union.